Bgm (BGM) Income towards Parent Company (2019 - 2025)
Bgm's (BGM) quarterly Income towards Parent Company came in at $182.1 million in Q1 2025, up 319.33% year-on-year from $43.4 million in Q1 2024, and up 326.08% on a QoQ basis from $42.7 million in Q3 2024.
Bgm (BGM) Income towards Parent Company (2019 - 2025) Analysis & Trends
Bgm (BGM) has 7 years of Income towards Parent Company data on file, last reported at $182.1 million in Q1 2025.
- On a quarterly basis, Income towards Parent Company rose 319.33% year-over-year to $182.1 million in Q1 2025; TTM through Mar 2025 was $182.1 million, a 319.33% increase from a year earlier, with the FY2025 full-year figure at -$20.0 million, down 146.9% from the prior year.
- Income towards Parent Company for Q1 2025 stood at $182.1 million, up from $42.7 million in the prior quarter.
- Over the last five years, Income towards Parent Company for BGM reached as high as $55477.7 billion in Q1 2022 and fell as low as $42.7 million in Q3 2024.
- Historically, Income towards Parent Company has averaged $27029.3 billion across 5 years, with a median of $26423.0 billion in 2023.
- Across the five-year window, Income towards Parent Company soared 210200352.64% in 2021 and plunged 100.0% in 2023, its largest moves.
- Year by year, Income towards Parent Company stood at $54858.6 billion in 2021, then dropped by 3.29% to $53052.1 billion in 2022, then plunged by 100.0% to $42.8 million in 2023, then slipped by 0.11% to $42.7 million in 2024, then surged by 326.08% to $182.1 million in 2025.
- Per Business Quant data, the three most recent Income towards Parent Company figures were $182.1 million in Q1 2025, $42.7 million in Q3 2024, and $43.4 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Bgm | 33.55 Mn | 23.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 182.12 Mn |
| Sep 30, 2024 | 42.74 Mn |
| Mar 31, 2024 | 43.43 Mn |
| Sep 30, 2023 | 42.79 Mn |
| Mar 31, 2023 | 52,845.84 Bn |
| Sep 30, 2022 | 53,052.14 Bn |
| Mar 31, 2022 | 55,477.71 Bn |
| Sep 30, 2021 | 54,858.61 Bn |
| Sep 30, 2020 | 26.10 Mn |
| Sep 30, 2019 | 19,893.35 Bn |